Recro Pharma Inc (REPH) Expected to Post Quarterly Sales of $13.32 Million
Analysts predict that Recro Pharma Inc (NASDAQ:REPH) will post $13.32 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Recro Pharma’s earnings, with estimates ranging from $13.30 million to $13.35 million. Recro Pharma posted sales of $17.36 million during the same quarter last year, which suggests a negative year over year growth rate of 23.3%. The company is expected to report its next earnings results on Monday, March 5th.
According to Zacks, analysts expect that Recro Pharma will report full-year sales of $13.32 million for the current year, with estimates ranging from $62.50 million to $66.14 million. For the next financial year, analysts expect that the firm will post sales of $66.09 million per share, with estimates ranging from $63.60 million to $70.93 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.27. Recro Pharma had a negative net margin of 51.88% and a negative return on equity of 60.01%.
In other news, major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $9.50, for a total value of $973,180.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of Recro Pharma stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total transaction of $115,120.32. Following the completion of the sale, the insider now owns 734,269 shares of the company’s stock, valued at $6,520,308.72. The disclosure for this sale can be found here. Insiders have sold 860,414 shares of company stock valued at $8,289,916 over the last 90 days. Company insiders own 21.60% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in shares of Recro Pharma by 183.4% in the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 14,098 shares in the last quarter. Teachers Advisors LLC acquired a new stake in shares of Recro Pharma in the second quarter valued at approximately $162,000. California State Teachers Retirement System acquired a new stake in shares of Recro Pharma in the second quarter valued at approximately $169,000. Wells Fargo & Company MN raised its position in shares of Recro Pharma by 42.5% in the third quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock valued at $220,000 after buying an additional 7,308 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of Recro Pharma in the second quarter valued at approximately $215,000. Institutional investors own 61.55% of the company’s stock.
Shares of Recro Pharma (NASDAQ REPH) traded up $0.04 during mid-day trading on Thursday, reaching $8.93. 163,894 shares of the company’s stock traded hands, compared to its average volume of 87,771. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.59 and a quick ratio of 1.35. The firm has a market capitalization of $170.80, a P/E ratio of -4.08 and a beta of -0.50. Recro Pharma has a 1 year low of $5.81 and a 1 year high of $10.59.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.